DarioHealth Corp. cash flow to debt ratio of -81.71% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

DarioHealth Corp.'s free cash flow has increased -32.60% from $-38.70M last year to $-26.08M, signaling increasing performance

DarioHealth Corp.'s debt to equity ratio is 0.59, which means that the company's assets are healthy financed, signaling financial stability.

DarioHealth Corp.'s debt has increased relative to shareholder equity from 0.42 last year to 0.59 today, signaling weakened financials

DarioHealth Corp. has negative EBITDA, making leverage ratio unreliable

DarioHealth Corp.'s interest coverage ratio is -12.36, which means that the company struggles to meet interest obligations, signaling financial risk.

DarioHealth Corp.'s profit margin has increased (-304.17%) in the last year from -158.09% to 322.77%, signaling increasing performance

DarioHealth Corp.'s short-term assets of $34.81M exceed its short-term liabilities of $9.32M

DarioHealth Corp.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

DarioHealth Corp.'s return on equity of 104.15%, is higher than 15.00%, indicating good performance

DarioHealth Corp.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

DarioHealth Corp. had positive net income in only 0 out of 5 years, indicating unstable earnings

DarioHealth Corp. has negative free cash flow, indicating the company is burning cash rather than generating it

DarioHealth Corp. has negative free cash flow, indicating cash burn

DarioHealth Corp.'s yearly earnings has increased -2.42% since last year from $-42.75M to $-41.71M, signaling increasing performance

DarioHealth Corp.'s yearly revenue has decreased 17.31% since last year from $27.04M to $22.36M, signaling decreasing performance

ROIC 762.65% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.

DarioHealth Corp.'s 3-year revenue CAGR of -6.84% is negative, indicating declining revenue over the past 3 years

DarioHealth Corp. had revenue growth in 3 out of 5 years, indicating consistent revenue performance

DarioHealth Corp. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

DarioHealth Corp. has insufficient data to evaluate this check.

DarioHealth Corp. has an earnings yield of 94.70%, which is above the 4.00% threshold, indicating the stock offers reasonable value relative to its earnings

DarioHealth Corp. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

DarioHealth Corp. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

DarioHealth Corp. is overvalued relative to its fair value price of -18.62 based on Earnings Fair Value model

DarioHealth Corp. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

DarioHealth Corp. has negative shareholder equity; price-to-book is not meaningful and the check fails

DarioHealth Corp. has a price-to-sales ratio of 3.41x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue